# Gemcitabine and Bexarotene in Treating Patients With Progressive or Refractory Stage IB, Stage II, Stage III, or Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma

> **NCT00660231** · PHASE2 · COMPLETED · sponsor: **University College, London** · enrollment: 36 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** bexarotene
- **DRUG:** gemcitabine hydrochloride

## Key facts

- **NCT ID:** NCT00660231
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2011-09
- **Final completion:** 2014-01
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2014-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00660231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00660231, "Gemcitabine and Bexarotene in Treating Patients With Progressive or Refractory Stage IB, Stage II, Stage III, or Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00660231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*